Author: Zhang, Hui ; Lin, Xueyuan ; Li, Mingwei ; Wang, Lifeng ; Dong, Liyun ; Zhang, Guoqing ; Zhang, Jiwen ; Wu, Li ; Wang, Zhigang ; Ye, Xinyue ; Wang, Weixing ; Li, Falan ; Chen, Weidong ; Peng, Can

Controlled release drug delivery systems of eye drops are a promising ophthalmic therapy with advantages of good patient compliance and low irritation. However, the lack of a suitable drug carrier for ophthalmic use limits the development of the aforementioned system. Herein, the crosslinked cyclodextrin organic framework (COF) with a cubic porous structure and a uniform particle size was synthesized and applied to solidify vitamin A palmitate (VAP) by using the solvent-free method. The VAP@COF suspension eye drops were formulated by screening co-solvents, suspending agents, and stabilizing agents to achieve a homogeneous state and improve stability. According to the in vitro release study, the VAP@COF suspension exhibited a controlled release of VAP within 12 h. Both the ex vivo corneal contact angle and in vivo fluorescence tracking indicated that the VAP@COF suspension prolonged the VAP residence time on the ocular surface. This suspension accelerated the recovery of the dry eye disease (DED) model in New Zealand rabbits. Furthermore, the suspension was non-cytotoxic to human corneal epithelial cells and non-irritation to rabbit eyes. In summary, the particulate COF is an eye-acceptable novel carrier that sustains release and prolongs the VAP residence time on the ocular surface for DED treatment.

01 May 2024·Journal of Stroke and Cerebrovascular Diseases

Velvet antler polypeptide (VAP) protects against cerebral ischemic injury through NF-κB signaling pathway in vitro

Article

Author: Li, Yutao ; Wu, Qian ; Ge, Ying ; Ye, Ru ; Wang, Hui

OBJECTIVEVelvet antler polypeptide (VAP) has been shown to play important roles in the immune and nervous systems. The purpose of this study was to investigate the protective effects of VAP on cerebral ischemic injury with the involvement of NF-κB signaling pathway in vitro.MATERIALS AND METHODSPC-12 cells stimulated by oxygen-glucose deprivation/reperfusion (OGD/R) was used to mimic cerebral ischemic injury in vitro. The levels of ROS, SOD, and intracellular concentrations of Ca2+ were measured by the relevant kits. Meanwhile, the expressions of inflammatory cytokines (IL-6, IL-1β, and TNF-α) were determined by ELISA kit assay. In addition, MTT, EdU, and flow cytometry assays were used to measure the cell proliferation and apoptosis. Besides which, the related proteins of NF-κB signaling pathway were measured by western blotting assay.RESULTSVAP alleviated cerebral ischemic injury by reducing OGD/R-induced oxidative stress, inflammation, and apoptosis in PC-12 cells in a time dependent manner. Mechanistically, VAP inhibited the levels of p-p65 and p-IkB-α in a time dependent manner, which was induced by OGD/R operation. Moreover, NF-κB agonist diprovocim overturned the suppression effects of VAP on OGD/R-induced oxidative stress, inflammation, and apoptosis in PC-12 cells.CONCLUSIONSThe results demonstrate that VAP may alleviate cerebral ischemic injury by suppressing the activation of NF-κB signaling pathway.

04 Jul 2023·ACS omega

Hypericum perforatum Oil and Vitamin A Palmitate-Loaded Gelatin Nanofibers Cross-Linked by Tannic Acid as Wound Dressings.

Article

Author: Karbancioglu-Guler, Funda ; Erol-Taygun, Melek ; Akturk, Aysen ; Dikmetas, Dilara Nur ; Kasikci, Funda Nur

Recent studies in wound dressing applications offer new therapies to promote the wound healing process. The main strategy of this study is to combine the traditional perspective of using medicinal oils with polymeric scaffolds manufactured by an engineering approach to fabricate a potential tissue engineering product that provides both new tissue formation and wound healing. Thus, Hypericum perforatum oil (HPO) and vitamin A palmitate (VAP) incorporated gelatin (Gt) nanofibrous scaffolds were successfully prepared by the electrospinning method. Tannic acid (TA) was used as the cross-linking agent. The amounts of VAP and HPO loaded in the base Gt solution [15% w/v in 4:6 v/v acetic acid/deionized water] were 5 and 50 wt % (based on the weight of Gt), respectively. The obtained scaffolds were studied regarding their microstructure, chemical structure, thermal stability, antibacterial activity, in vitro release study, and cellular proliferation assay. In the light of these studies, it was determined that VAP and HPO were incorporated successfully in Gt nanofibers cross-linked with TA. Release kinetic tests confirmed that the patterns of TA and VAP release were consistent with the Higuchi model, whereas HPO release was consistent with the first-order kinetic model. In addition, this membrane was biocompatible with L929 fibroblast cells and had antibacterial activity and thermal stability. This preliminary study suggests potential applicability of the proposed dressing to treat skin wounds in clinics.

100 Deals associated with Prostate cancer vaccine(FK Biotecnologia SA)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Prostatic Cancer	Phase 2	-	FK Biotecnologia SA	-
Prostatic Cancer	Phase 2	-	Universidade Federal do Rio Grande do Sul	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Prostate cancer vaccine(FK Biotecnologia SA)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation